0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

JAMA Oncology | 
Brief Report |  ONLINE FIRST
Kenar D. Jhaveri, MD; Vipulbhai Sakhiya, MBBS; Steven Fishbane, MD
JAMA Oncol. Published online June 25, 2015. doi:10.1001/jamaoncol.2015.1713

JAMA Oncology | 
Invited Commentary |  ONLINE FIRST
Bart L. Scott, MD; Pamela S. Becker, MD, PhD
JAMA Oncol. Published online June 18, 2015. doi:10.1001/jamaoncol.2015.1591

JAMA Oncology | 
Original Investigation |  ONLINE FIRST
Animesh Pardanani, MD; Claire Harrison, MD; Jorge E. Cortes, MD; et al.
JAMA Oncol. Published online June 18, 2015. doi:10.1001/jamaoncol.2015.1590
Includes: Supplemental Content

JAMA | 
Medical News & Perspectives | 
Rita Rubin, MA
JAMA. 2015;313(23):2309-2310. doi:10.1001/jama.2015.3911.

JAMA Psychiatry | 
Original Investigation | 
Yaron Finkelstein, MD, ABCP(Dip); Erin M. Macdonald, MSc; Simon Hollands, MSc; et al.
JAMA Psychiatry. 2015;72(6):570-575. doi:10.1001/jamapsychiatry.2014.3188.
Includes: Supplemental Content

JAMA Dermatology | 
Original Investigation | 
Steven M. Belknap, MD; Imran Aslam, BS; Tina Kiguradze, BS; et al.
JAMA Dermatol. 2015;151(6):600-606. doi:10.1001/jamadermatol.2015.36.

JAMA Dermatology | 
Research Letter | 
Robert Denison Griffith, MD; Brian J. Simmons, BSc; Mohammad-Ali Yazdani Abyaneh, BSc; et al.
JAMA Dermatol. 2015;151(6):667-668. doi:10.1001/jamadermatol.2015.120.

JAMA Ophthalmology | 
Observation | 
Michael J. Koziolek, MD; Daniel Patschan, MD; Herbert Desel, MD; et al.
JAMA Ophthalmol. 2015;133(6):718-720. doi:10.1001/jamaophthalmol.2015.191.
Includes: Supplemental Content

JAMA Internal Medicine | 
Invited Commentary | 
Hillary V. Kunins, MD, MPH, MS
JAMA Intern Med. 2015;175(6):987-988. doi:10.1001/jamainternmed.2015.0939.

JAMA Internal Medicine | 
Original Investigation | 
Marc R. Larochelle, MD, MPH; Fang Zhang, PhD; Dennis Ross-Degnan, ScD; et al.
JAMA Intern Med. 2015;175(6):978-987. doi:10.1001/jamainternmed.2015.0914.
Includes: CME, Supplemental Content

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib
Kenar D. Jhaveri, MD; Vipulbhai Sakhiya, MBBS; Steven Fishbane, MD
JAMA Oncology
Invited Commentary  | 
JAK/STAT Pathway Inhibitors and Neurologic Toxicity: Above All Else Do No Harm?
Bart L. Scott, MD; Pamela S. Becker, MD, PhD
JAMA Oncology
Original Investigation  | 
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial
Animesh Pardanani, MD; Claire Harrison, MD; Jorge E. Cortes, MD; et al.
JAMA
Medical News & Perspectives  | 
Margaret A. Hamburg, MD, Reflects on 6 Years at FDA
Rita Rubin, MA